Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib Phase IV in EGFRm+ NSCLC after Platinum Chemo
NCT02208843Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, open-label, single-arm trial of afatinib in lung adenocarcinoma (LUAD), sponsored by Boehringer Ingelheim. Primary endpoint: Objective Tumour Response up to 802 days. Started Oct 2014; status: completed.
02
Drugs
afatinib
03
Conditions
lung adenocarcinoma (LUAD)
Beyond the preview
Go deeper on NCT02208843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02208843.